DNA Funded vs FundedNext (2026) — Which Is Better?

Positioning

DNA Funded and FundedNext are both prop firms offering funded trading accounts through challenge-based evaluation, but they target different trader profiles. DNA Funded operates under the backing of an ASIC-regulated broker, prioritizing regulatory credibility and asset breadth, while FundedNext emphasizes capital scaling and automation-friendly features. Both charge $49/month and offer similar challenge structures, but their approaches to profit splits, instrument selection, and regulatory oversight diverge significantly.

Total Cost Breakdown

Both firms charge identical monthly subscriptions of $49, making baseline costs a non-factor in this decision. However, the real pricing difference lies in challenge fees and profit potential. DNA Funded's challenge fees are refunded upon your first profitable payout—a meaningful advantage if you fail early and want to try again without additional out-of-pocket spending. FundedNext charges one-time fees across six account sizes (with capital up to $200K) but does not refund these fees, meaning failed attempts cost you repeatedly. DNA Funded's 80% base profit split is lower than FundedNext's up to 90%, but FundedNext's higher split only materializes if you scale to larger accounts ($4 million). For traders starting with standard account sizes ($25K–$50K), the effective profit split difference is negligible, and DNA Funded's fee-refund policy provides better value on the first challenge attempt.

What You Actually Get

Regulatory Backing: DNA Funded is backed by DNA Markets, an ASIC-regulated Australian broker—exceptionally rare among prop firms. This means your funds are held by a licensed entity with actual regulatory oversight. FundedNext, based in Dubai, operates in a jurisdiction with weaker regulatory guardrails. For risk-averse traders, DNA's backing is not a minor feature; it's foundational credibility that most prop firms simply don't have.

Instrument Selection: DNA Funded offers 800+ CFD instruments with raw spreads from 0.0 pips via TradeLocker. FundedNext has fewer tradable instruments than "some multi-asset prop firm competitors," which is vague and suggests a narrower product suite. If you trade exotic pairs, emerging-market stocks, or niche commodities, DNA Funded's breadth is a clear advantage.

Automation & Expert Advisors: FundedNext explicitly allows expert advisors and fully automated trading strategies. DNA Funded's terms don't mention this. If algorithmic or EA-based trading is core to your strategy, FundedNext removes friction here; you won't need to ask for permission or worry about hidden restrictions.

Profit Sharing During Evaluation: FundedNext allows you to earn a percentage of profits during your evaluation phase before being fully funded. DNA Funded does not mention this. This transforms FundedNext's 1 and 2-phase challenges into partial income opportunities rather than pure evaluation costs, which appeals to traders who want to offset evaluation risk with live trading income.

Challenge Flexibility: DNA Funded offers four challenge types—1-Phase, 2-Phase, Rapid, and Instant Funding—with no time limits on 1-Phase and 2-Phase. This is valuable for deliberate traders who don't want to rush under pressure. FundedNext's 1 and 2-phase structure is more standard but less flexible.

Community & Track Record: FundedNext (founded 2022) has a 2-year operational history and a higher rating (4.2/5 vs 3.9/5). DNA Funded (founded 2024) is newer but benefits from being backed by an established broker. If you value community feedback and long-term stability, FundedNext's extra year matters; if you prioritize regulatory credibility over community size, DNA Funded's broker backing trumps this.

Who Should Choose DNA Funded

- Traders prioritizing regulatory security: If you're uncomfortable with unregulated offshore environments, DNA Funded's ASIC backing removes a major concern and provides legal recourse in case of disputes.
- Multi-asset, spread-sensitive traders: If you scalp, trade exotic pairs, or need raw spreads under 1 pip, DNA Funded's 800+ instruments and 0.0 pip spreads are substantially better than competitors offering fewer assets.
- First-time prop firm challengers: The fee-refund policy on your first payout makes your first challenge a genuine free trial if you're profitable—a unique advantage that reduces downside risk.
- Traders avoiding time pressure: If you trade patience-heavy strategies (swing trading, position trading) and dislike artificial time constraints, DNA Funded's unlimited evaluation periods are a better fit than typical 30–60 day windows.

Who Should Choose FundedNext

- Algorithmic and EA traders: If your edge relies on expert advisors or fully automated strategies, FundedNext's explicit support for this removes ambiguity and legal friction.
- Capital scalers: If your goal is to grow from a $25K funded account to $100K+ over time, FundedNext's scaling structure and up-to-90% profit splits at higher tiers reward consistent performance with better margins.
- Traders wanting evaluation income: If you want to offset challenge costs by earning profit-sharing during the evaluation phase, FundedNext's dual-income model is unique and appeals to traders who perform well in live conditions.
- Risk-aware traders seeking transparency: FundedNext's higher rating (4.2/5), 2022 founding, and clear dashboard appeal to traders who value community feedback and established operational history over newer, lesser-known alternatives.

The Verdict, Plainly

DNA Funded wins for traders who demand regulatory credibility, need diverse instruments, and trade spread-sensitive strategies—the ASIC backing is irreplaceable. FundedNext wins for algorithmic traders, account scalers, and those willing to trade on a Dubai-regulated platform in exchange for profit-sharing during evaluation and a higher profit split ceiling. If safety and asset diversity matter most, DNA Funded is the choice; if automation and capital growth matter most, FundedNext edges ahead despite the regulatory trade-off.